Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails

NCT ID NCT05063552

Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests three different drug combinations in 430 adults with advanced head and neck cancer that has spread or returned after prior immunotherapy. The goal is to see if adding bevacizumab to standard chemo, or using atezolizumab plus bevacizumab, works better than the usual chemo plus cetuximab. The trial aims to improve survival and control the disease, not cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 430 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient must have histologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (excluding squamous cell carcinoma \[SCC\] of salivary glands, Epstein-Barr virus \[EBV\]-associated nasopharynx and skin) * Patient must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Measurements must be obtained within 4 weeks prior to randomization * Patient must be \>= 18 years of age * Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Patient must have disease progression after prior therapy with an immune checkpoint inhibitor (ICI) in the first-line setting for recurrent/metastatic disease. Patient must have received first-line immune checkpoint inhibition for at least 6 weeks. Patients who have recurred or progressed within 12 weeks of immune checkpoint inhibition administered in the definitive setting for locally advanced disease (for e.g., in the context of a clinical trial) will also be eligible if local therapies are not feasible * Prior combination immunotherapies are permitted, but patient must not have had prior antiangiogenic treatment (e.g., bevacizumab, ziv-aflibercept, ramucirumab, sorafenib, sunitinib, pazopanib, regorafenib, lenvatinib, etc.). Patient must have completed any prior investigational therapy at least 28 days prior to randomization. * NOTE: Patients who received platinum/taxanes in the locally-advanced or recurrent/metastatic setting and did not progress for at least 4 months thereafter, will be eligible for this study. Patients who received cetuximab in the locally-advanced setting and did not progress for at least 4 months thereafter, will also be eligible for this study * Patient must not have a history of \>= grade 3 immune-related adverse event on prior ICI therapy (except those that could be managed with steroids \[e.g., dermatologic toxicity, asymptomatic elevation of pancreatic enzymes, etc.\]) and ICI could eventually be resumed. Patients who developed grade 3 endocrinopathies but are now stable on hormone supplementation and/or a daily prednisone dose of =\< 10 mg (or equivalent doses of another glucocorticoid), will be permitted on this trial * Patient must not have a history of PD-1 inhibitor-induced hyper-progression, defined as 100% increase in tumor burden within 8 weeks (or 50% within 4 weeks) of initiating ICI and associated with clinical deterioration * Patient must not have any of the following criteria due to the possibility of increased risk for tumor bleeding with bevacizumab therapy: * Prior carotid bleeding, * Tumors that invade major vessels (e.g., the carotid) as shown unequivocally by imaging studies, * Central (e.g., within 2 cm from the hilum) lung metastases that are cavitary as shown unequivocally by imaging studies, * Any prior history of bleeding related to the current head and neck cancer, * History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode of coughing) within 3 months prior to randomization * Patient must not have uncontrolled hypertension, a history of hypertensive crisis or hypertensive encephalopathy, or a history of grade 4 thromboembolism * Patient must not have a history of coagulopathy or hemorrhagic disorders * Patient must not have a history of thrombosis (e.g., pulmonary embolism or deep venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use of anticoagulation is allowed) * Patient must not be receiving chronic daily treatment with aspirin (\> 325 mg/day) or non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function. The use of anti-platelet agents \[e.g., dipyridamole (Persatine), ticlopidine (Ticlid), clopidogrel (Plavix)\] is allowed only if patient is not receiving concurrent aspirin or NSAID's known to inhibit platelet function * Patient must have PD-L1 expression \>= 1% by CPS in the tumor and/or immune cells * NOTE: Enrolling centers should test for PD-L1 CPS preferably using the SP263 assay. Where this is not feasible, using their preferred Clinical Laboratory Improvement Act (CLIA)-certified or similar assay will be accepted. It is preferred for standard of care (SOC) PD-L1 assessments to be done on post-first line ICI samples if available, but SOC PD-L1 assessments on pre-ICI samples will be accepted for eligibility * Patient must not have a severe infection within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. Patients must not have active tuberculosis * Patient must not have a history of non-infectious pneumonitis requiring steroids at doses greater than or equal to 10 mg per day of prednisone or the equivalent on first line immunotherapy * Patient must not have a history of solid organ transplantation or stem-cell transplant * Patient must not be on immunosuppressive medication within 7 days prior to randomization except for: intranasal, inhaled, or topical steroids, local steroid injection, systemic corticosteroids at doses less than or equal to 10 mg per day of prednisone or the equivalent, or steroids used as premedication for hypersensitivity reactions * Patient must not have an active autoimmune disease that requires systemic treatment within 2 years prior to randomization. Patients who are receiving replacement therapy for adrenal or pituitary insufficiency will not be excluded * Patient must not have had a severe hypersensitivity reaction to any of the drug components used on this protocol or to chimeric or humanized antibodies or fusion proteins * Patient must not have received any live vaccine within 30 days prior to randomization and while participating in the study (and continue for 5 months after the last dose of atezolizumab on Arm C). Live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 2019 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist \[registered trademark\] are live attenuated vaccines and are not allowed). If possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events * Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. * All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. * A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months) * Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of protocol treatment for patients assigned to Arms B or C. * NOTE: Patients must also not breastfeed while on treatment and for 2 months after the last dose of treatment for patients assigned to Arm A and for 6 months after the last dose of treatment for patients assigned to Arms B or C * Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible * Leukocytes \>= 3,000/mcL (must be obtained =\< 14 days prior to protocol randomization) * Absolute neutrophil count (ANC) \>= 1,500/mcL (must be obtained =\< 14 days prior to protocol randomization) * Platelets \>= 100,000/mcL (must be obtained =\< 14 days prior to protocol randomization) * Hemoglobin (Hgb) \> 9 g/dL (must be obtained =\< 14 days prior to protocol randomization) (Note: Patient may be transfused to meet this criteria) * Total bilirubin =\< 2.0 x institutional upper limit of normal (ULN) (=\< 5.0 x institutional ULN if hepatic metastases present or =\< 3 x ULN for patients with known Gilbert's disease) (must be obtained =\< 14 days prior to protocol randomization) * Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x institutional ULN (\< 5.0 x institutional ULN if hepatic metastases present) (must be obtained =\< 14 days prior to protocol randomization) * Alkaline phosphatase \< 2.5 x institutional ULN (\< 5.0 x institutional ULN if hepatic or bone metastases present) (must be obtained =\< 14 days prior to protocol randomization) * Creatinine =\< 1.5 x institutional ULN (must be obtained =\< 14 days prior to protocol randomization) * Patients with uncontrolled or symptomatic hypercalcemia (ionized calcium \> 1.5 mmol/L, calcium \> 12 mg/dL or corrected serum calcium \> ULN) must have their calcium levels corrected prior to randomization * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial * For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated * Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load * Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients must not have untreated brain metastases or leptomeningeal disease * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Patients must not have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients may have indwelling catheters (e.g., PleurX \[registered trademark\]) * Patient must not have significant cardiovascular disease (such as New York Heart Association class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to randomization, or unstable arrhythmia or unstable angina at the time of randomization * Patient must not receive any other chemotherapy, immunotherapy, antitumor hormonal therapy (excluding contraceptives and replacement steroids), radiation therapy, or experimental medications while on protocol treatment. Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to randomization and patients must be recovered from the effects of radiation (there is no required minimum recovery period * Patient must not have had a surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to randomization, or anticipation of need for major surgical procedure while on protocol treatment * Patient must not have any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of the agents used in this protocol, may affect the interpretation of the results, or may render the patient at high risk from treatment complications * Patient must not have a history of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, or active GI bleeding within 6 months prior to randomization

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical stage IV HPV-mediated (P16-positive) oropharyngeal carcinoma ajcc V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma head and neck squamous cell carcinoma hypopharyngeal carcinoma hypopharynx cancer hypopharynx squamous cell carcinoma laryngeal carcinoma laryngeal neoplasm laryngeal squamous cell carcinoma larynx cancer lip and oral cavity carcinoma lip and oral cavity squamous cell carcinoma lymphoid interstitial pneumonia metastatic squamous cell carcinoma Mouth Neoplasms nasal cavity and paranasal sinus squamous cell carcinoma nasal cavity squamous cell carcinoma nasopharyngeal carcinoma nasopharyngeal squamous cell carcinoma oropharyngeal carcinoma oropharynx cancer oropharynx squamous cell carcinoma pharyngeal squamous cell carcinoma skin squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical stage IV HPV-mediated (P16-positive) oropharyngeal carcinoma ajcc V8 Metastatic head and neck squamous cell carcinoma Metastatic hypopharyngeal squamous cell carcinoma Metastatic laryngeal squamous cell carcinoma Metastatic lip and oral cavity carcinoma Metastatic nasal cavity squamous cell carcinoma Metastatic nasopharyngeal squamous cell carcinoma Metastatic pharyngeal squamous cell carcinoma Metastatic sinonasal squamous cell carcinoma Recurrent head and neck squamous cell carcinoma Recurrent hypopharyngeal squamous cell carcinoma Recurrent laryngeal squamous cell carcinoma Recurrent lip and oral cavity squamous cell carcinoma Recurrent nasopharyngeal squamous cell carcinoma Recurrent pharyngeal squamous cell carcinoma Recurrent sinonasal squamous cell carcinoma Stage IV head and neck cutaneous squamous cell carcinoma ajcc V8 Stage IV hypopharyngeal carcinoma ajcc V8 Stage IV laryngeal cancer ajcc V8 Stage IV lip and oral cavity cancer ajcc V8 Stage IV nasopharyngeal carcinoma ajcc V8 Stage IV oropharyngeal (P16-negative) carcinoma ajcc V8 Stage IV sinonasal cancer ajcc V8

Contacts and locations

Locations

  • Abbott-Northwestern Hospital

    Minneapolis, Minnesota, 55407, United States

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania, 15212, United States

  • Arnold Palmer Cancer Center Medical Oncology Norwin

    N. Huntingdon, Pennsylvania, 15642, United States

  • Asplundh Cancer Pavilion

    Willow Grove, Pennsylvania, 19090, United States

  • Atrium Medical Center-Middletown Regional Hospital

    Franklin, Ohio, 45005-1066, United States

  • Benefis Sletten Cancer Institute

    Great Falls, Montana, 59405, United States

  • Billings Clinic Cancer Center

    Billings, Montana, 59101, United States

  • Bozeman Health Deaconess Hospital

    Bozeman, Montana, 59715, United States

  • Broward Health Medical Center

    Fort Lauderdale, Florida, 33316, United States

  • Cancer Care Center of O'Fallon

    O'Fallon, Illinois, 62269, United States

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois, 62526, United States

  • Carle Cancer Center

    Urbana, Illinois, 61801, United States

  • Carle Physician Group-Effingham

    Effingham, Illinois, 62401, United States

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois, 61938, United States

  • Carle at The Riverfront

    Danville, Illinois, 61832, United States

  • Carlisle Regional Cancer Center

    Carlisle, Pennsylvania, 17015, United States

  • Centralia Oncology Clinic

    Centralia, Illinois, 62801, United States

  • Community Hospital of Anaconda

    Anaconda, Montana, 59711, United States

  • Community Medical Center

    Missoula, Montana, 59804, United States

  • Contra Costa Regional Medical Center

    Martinez, California, 94553-3156, United States

  • Covenant Health Cancer Centers

    Knoxville, Tennessee, 37916, United States

  • Covenant Health Cancer Centers - West

    Knoxville, Tennessee, 37932, United States

  • Covenant Health Oncology Group - Lenoir City

    Lenoir City, Tennessee, 37772, United States

  • Covenant Health Oncology Group - Oak Ridge

    Oak Ridge, Tennessee, 37830, United States

  • Crossroads Cancer Center

    Effingham, Illinois, 62401, United States

  • Dartmouth Cancer Center - North

    Saint Johnsbury, Vermont, 05819, United States

  • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

    Lebanon, New Hampshire, 03756, United States

  • Dayton Physician LLC - Englewood

    Dayton, Ohio, 45415, United States

  • Decatur Memorial Hospital

    Decatur, Illinois, 62526, United States

  • Divine Providence Hospital

    Williamsport, Pennsylvania, 17754, United States

  • Emory University Hospital Midtown

    Atlanta, Georgia, 30308, United States

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Epic Care Partners in Cancer Care

    Emeryville, California, 94608, United States

  • Epic Care-Dublin

    Dublin, California, 94568, United States

  • Forbes Hospital

    Monroeville, Pennsylvania, 15146, United States

  • Greater Baltimore Medical Center

    Baltimore, Maryland, 21204, United States

  • Greater Regional Medical Center

    Creston, Iowa, 50801, United States

  • HSHS Saint Elizabeth's Hospital

    O'Fallon, Illinois, 62269, United States

  • Hawaii Cancer Care - Westridge

    ‘Aiea, Hawaii, 96701, United States

  • Hawaii Cancer Care Inc - Waterfront Plaza

    Honolulu, Hawaii, 96813, United States

  • Helen F Graham Cancer Center

    Newark, Delaware, 19713, United States

  • Hennepin County Medical Center

    Minneapolis, Minnesota, 55415, United States

  • IRMC Cancer Center

    Indiana, Pennsylvania, 15701, United States

  • Ingalls Memorial Hospital

    Harvey, Illinois, 60426, United States

  • Iowa Methodist Medical Center

    Des Moines, Iowa, 50309, United States

  • Jefferson Torresdale Hospital

    Philadelphia, Pennsylvania, 19114, United States

  • John H Stroger Jr Hospital of Cook County

    Chicago, Illinois, 60612, United States

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Kettering Medical Center

    Kettering, Ohio, 45429, United States

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho, 83854, United States

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho, 83864, United States

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho, 83814, United States

  • Mary Greeley Medical Center

    Ames, Iowa, 50010, United States

  • McFarland Clinic - Ames

    Ames, Iowa, 50010, United States

  • McFarland Clinic - Boone

    Boone, Iowa, 50036, United States

  • McFarland Clinic - Jefferson

    Jefferson, Iowa, 50129, United States

  • McFarland Clinic - Marshalltown

    Marshalltown, Iowa, 50158, United States

  • McFarland Clinic - Trinity Cancer Center

    Fort Dodge, Iowa, 50501, United States

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia, 20010, United States

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware, 19713, United States

  • Memorial Medical Center-Las Cruces

    Las Cruces, New Mexico, 88011, United States

  • Mercy Cancer Center-West Lakes

    Clive, Iowa, 50325, United States

  • Mercy Hospital

    Coon Rapids, Minnesota, 55433, United States

  • Mercy Hospital South

    St Louis, Missouri, 63128, United States

  • Mercy Medical Center - Des Moines

    Des Moines, Iowa, 50314, United States

  • Mercy Medical Center-West Lakes

    West Des Moines, Iowa, 50266, United States

  • Miami Valley Cancer Care and Infusion

    Greenville, Ohio, 45331, United States

  • Miami Valley Hospital

    Dayton, Ohio, 45409, United States

  • Miami Valley Hospital North

    Dayton, Ohio, 45415, United States

  • Miami Valley Hospital South

    Centerville, Ohio, 45459, United States

  • Park Nicollet Clinic - Saint Louis Park

    Saint Louis Park, Minnesota, 55416, United States

  • Premier Blood and Cancer Center

    Dayton, Ohio, 45409, United States

  • ProHealth D N Greenwald Center

    Mukwonago, Wisconsin, 53149, United States

  • ProHealth Oconomowoc Memorial Hospital

    Oconomowoc, Wisconsin, 53066, United States

  • Providence Cancer Institute Clackamas Clinic

    Clackamas, Oregon, 97015, United States

  • Providence Newberg Medical Center

    Newberg, Oregon, 97132, United States

  • Providence Portland Medical Center

    Portland, Oregon, 97213, United States

  • Providence Saint Vincent Medical Center

    Portland, Oregon, 97225, United States

  • Queen's Cancer Cenrer - POB I

    Honolulu, Hawaii, 96813, United States

  • Queen's Cancer Center - Kuakini

    Honolulu, Hawaii, 96817, United States

  • Queen's Medical Center

    Honolulu, Hawaii, 96813, United States

  • Rapid City Regional Hospital

    Rapid City, South Dakota, 57701, United States

  • Regions Hospital

    Saint Paul, Minnesota, 55101, United States

  • Rush-Copley Healthcare Center

    Yorkville, Illinois, 60560, United States

  • Rush-Copley Medical Center

    Aurora, Illinois, 60504, United States

  • Saint Francis Medical Center

    Cape Girardeau, Missouri, 63703, United States

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho, 83712, United States

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho, 83619, United States

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho, 83642, United States

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho, 83687, United States

  • Saint Luke's Cancer Institute - Twin Falls

    Twin Falls, Idaho, 83301, United States

  • Smilow Cancer Hospital Care Center - Guilford

    Guilford, Connecticut, 06437, United States

  • Smilow Cancer Hospital Care Center - Waterford

    Waterford, Connecticut, 06385, United States

  • Smilow Cancer Hospital Care Center - Westerly

    Westerly, Rhode Island, 02891, United States

  • Smilow Cancer Hospital Care Center at Glastonbury

    Glastonbury, Connecticut, 06033, United States

  • Smilow Cancer Hospital Care Center at Greenwich

    Greenwich, Connecticut, 06830, United States

  • Smilow Cancer Hospital Care Center at Long Ridge

    Stamford, Connecticut, 06902, United States

  • Smilow Cancer Hospital Care Center at Saint Francis

    Hartford, Connecticut, 06105, United States

  • Smilow Cancer Hospital Care Center-Fairfield

    Fairfield, Connecticut, 06824, United States

  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut, 06611, United States

  • Smilow Cancer Hospital-Derby Care Center

    Derby, Connecticut, 06418, United States

  • Smilow Cancer Hospital-Orange Care Center

    Orange, Connecticut, 06477, United States

  • Smilow Cancer Hospital-Torrington Care Center

    Torrington, Connecticut, 06790, United States

  • Smilow Cancer Hospital-Waterbury Care Center

    Waterbury, Connecticut, 06708, United States

  • Southeastern Medical Oncology Center-Clinton

    Clinton, North Carolina, 28328, United States

  • Southeastern Medical Oncology Center-Goldsboro

    Goldsboro, North Carolina, 27534, United States

  • Southeastern Medical Oncology Center-Jacksonville

    Jacksonville, North Carolina, 28546, United States

  • Southern Illinois University School of Medicine

    Springfield, Illinois, 62702, United States

  • Springfield Clinic

    Springfield, Illinois, 62702, United States

  • Springfield Memorial Hospital

    Springfield, Illinois, 62781, United States

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California, 94304, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • Toledo Clinic Cancer Centers-Toledo

    Toledo, Ohio, 43623, United States

  • Trinity's Tony Teramana Cancer Center

    Steubenville, Ohio, 43952, United States

  • UC Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois, 60451, United States

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California, 92868, United States

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California, 92612, United States

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic

    Ankeny, Iowa, 50023, United States

  • UI Health Care Mission Cancer and Blood - Des Moines Clinic

    Des Moines, Iowa, 50309, United States

  • UI Health Care Mission Cancer and Blood - Laurel Clinic

    Des Moines, Iowa, 50314, United States

  • UI Health Care Mission Cancer and Blood - Waukee Clinic

    Waukee, Iowa, 50263, United States

  • UI Health Care Mission Cancer and Blood - West Des Moines Clinic

    Clive, Iowa, 50325, United States

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida, 33146, United States

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida, 33442, United States

  • UM Sylvester Comprehensive Cancer Center at Kendall

    Miami, Florida, 33176, United States

  • UM Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida, 33324, United States

  • UMass Memorial Medical Center - University Campus

    Worcester, Massachusetts, 01655, United States

  • UPMC Altoona

    Altoona, Pennsylvania, 16601, United States

  • UPMC Camp Hill

    Camp Hill, Pennsylvania, 17011, United States

  • UPMC Cancer Center at UPMC Horizon

    Farrell, Pennsylvania, 16121, United States

  • UPMC Cancer Center at UPMC McKeesport

    McKeesport, Pennsylvania, 15132, United States

  • UPMC Cancer Center at UPMC Northwest

    Seneca, Pennsylvania, 16346, United States

  • UPMC Cancer Center-Natrona Heights

    Natrona Heights, Pennsylvania, 15065, United States

  • UPMC Cancer Center-Uniontown

    Uniontown, Pennsylvania, 15401, United States

  • UPMC Cancer Center-Washington

    Washington, Pennsylvania, 15301, United States

  • UPMC Cancer Centers - Arnold Palmer Pavilion

    Greensburg, Pennsylvania, 15601, United States

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • UPMC Hillman Cancer Center - Monroeville

    Monroeville, Pennsylvania, 15146, United States

  • UPMC Hillman Cancer Center - New Castle

    New Castle, Pennsylvania, 16105, United States

  • UPMC Hillman Cancer Center - Part of Frick Hospital

    Mount Pleasant, Pennsylvania, 15666, United States

  • UPMC Hillman Cancer Center - Passavant - Cranberry

    Cranberry Township, Pennsylvania, 16066, United States

  • UPMC Hillman Cancer Center Erie

    Erie, Pennsylvania, 16505, United States

  • UPMC Hillman Cancer Center at Butler Health System

    Butler, Pennsylvania, 16001, United States

  • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion

    Mechanicsburg, Pennsylvania, 17050, United States

  • UPMC Hillman Cancer Center in Coraopolis

    Moon Township, Pennsylvania, 15108, United States

  • UPMC Hillman Cancer Center in Greenville/UPMC Horizon

    Greenville, Pennsylvania, 16125, United States

  • UPMC Memorial

    York, Pennsylvania, 17408, United States

  • UPMC Pinnacle Cancer Center/Community Osteopathic Campus

    Harrisburg, Pennsylvania, 17109, United States

  • UPMC West Mifflin-Cancer Center Jefferson

    West Mifflin, Pennsylvania, 15122, United States

  • UPMC Western Maryland

    Cumberland, Maryland, 21502, United States

  • UPMC-Heritage Valley Health System Beaver

    Beaver, Pennsylvania, 15009, United States

  • UPMC-Johnstown/John P. Murtha Regional Cancer Center

    Johnstown, Pennsylvania, 15901, United States

  • UPMC-Mercy Hospital

    Pittsburgh, Pennsylvania, 15219, United States

  • UPMC-Passavant Hospital

    Pittsburgh, Pennsylvania, 15237, United States

  • UPMC-Saint Clair Hospital Cancer Center

    Pittsburgh, Pennsylvania, 15243, United States

  • UPMC-Saint Margaret

    Pittsburgh, Pennsylvania, 15215, United States

  • UW Cancer Center at ProHealth Care

    Waukesha, Wisconsin, 53188, United States

  • University Medical Center New Orleans

    New Orleans, Louisiana, 70112, United States

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas, 72205, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

  • University of Chicago Medicine-Orland Park

    Orland Park, Illinois, 60462, United States

  • University of Illinois

    Chicago, Illinois, 60612, United States

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland, 21201, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida, 33136, United States

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico, 87106, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • Upper Valley Medical Center

    Troy, Ohio, 45373, United States

  • VA Palo Alto Health Care System

    Palo Alto, California, 94304, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

  • West Virginia University Charleston Division

    Charleston, West Virginia, 25304, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

  • Yale-New Haven Hospital North Haven Medical Center

    North Haven, Connecticut, 06473, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.